Skip to main content
Novartis
language-selector-globe
Choose Location
  • International
  • Americas
  • Asia Pacific
  • Europe
  • Middle East & Africa
Global | English(link is external)
Novartis Foundation | English(link is external)
Argentina | Español(link is external)
Brazil | Português(link is external)
Canada | English(link is external)
Canada | Français(link is external)
Central America | Español(link is external)
Colombia | Español(link is external)
Mexico | Español(link is external)
United States | English(link is external)
Australia | English(link is external)
Bangladesh | English(link is external)
Hong Kong S.A.R. | 繁體中文(link is external)
India | English(link is external)
Indonesia | English(link is external)
Japan | 日本語(link is external)
Korea | 한국어(link is external)
Mainland China | 中文(link is external)
Malaysia | English(link is external)
Pakistan | English(link is external)
Philippines | English(link is external)
Singapore | English(link is external)
Taiwan | 繁體中文(link is external)
Thailand | ภาษาไทย(link is external)
Austria | Deutsch(link is external)
Belgium | Français(link is external)
Belgium | Nederlands(link is external)
Bulgaria | Български(link is external)
Czech Republic | Česky(link is external)
Czech Republic | English(link is external)
Denmark | Dansk(link is external)
Estonia | Eesti(link is external)
Finland | Suomalainen(link is external)
France | Français(link is external)
Germany | Deutsch(link is external)
Greece | Ελληνικά(link is external)
Hungary | Magyar(link is external)
Ireland | English(link is external)
Italy | Italiano(link is external)
Latvia | Latvian(link is external)
Lithuania | Lithuanian(link is external)
Netherlands | Nederlands(link is external)
Norway | Norsk(link is external)
Poland | Polski(link is external)
Portugal | Português(link is external)
Romania | Română(link is external)
Russia | Русский(link is external)
Serbia | Srpski(link is external)
Slovakia | Slovensky(link is external)
Slovenia | Slovenščina(link is external)
Slovenia | English(link is external)
Spain | Español(link is external)
Sweden | Svenska(link is external)
Switzerland | Deutsch(link is external)
Switzerland | Français(link is external)
Türkiye | Türkçe(link is external)
United Kingdom | English(link is external)
Egypt | English(link is external)
Israel | עברית(link is external)
Saudi Arabia | العربية(link is external)
South Africa | English(link is external)
language-selector-globe
Choose Location
International Americas Asia Pacific Europe Middle East & Africa
Argentina | Español(link is external)
Australia | English(link is external)
Austria | Deutsch(link is external)
Bangladesh | English(link is external)
Belgium | Français(link is external)
Belgium | Nederlands(link is external)
Brazil | Português(link is external)
Bulgaria | Български(link is external)
Canada | English(link is external)
Canada | Français(link is external)
Central America | Español(link is external)
Colombia | Español(link is external)
Czech Republic | Česky(link is external)
Czech Republic | English(link is external)
Denmark | Dansk(link is external)
Egypt | English(link is external)
Estonia | Eesti(link is external)
Finland | Suomalainen(link is external)
France | Français(link is external)
Germany | Deutsch(link is external)
Greece | Ελληνικά(link is external)
Hong Kong S.A.R. | 繁體中文(link is external)
Hungary | Magyar(link is external)
India | English(link is external)
Indonesia | English(link is external)
Ireland | English(link is external)
Israel | עברית(link is external)
Italy | Italiano(link is external)
Japan | 日本語(link is external)
Korea | 한국어(link is external)
Latvia | Latvian(link is external)
Lithuania | Lithuanian(link is external)
Mainland China | 中文(link is external)
Malaysia | English(link is external)
Mexico | Español(link is external)
Netherlands | Nederlands(link is external)
Norway | Norsk(link is external)
Global | English(link is external)
Novartis Foundation | English(link is external)
Pakistan | English(link is external)
Philippines | English(link is external)
Poland | Polski(link is external)
Portugal | Português(link is external)
Romania | Română(link is external)
Russia | Русский(link is external)
Saudi Arabia | العربية(link is external)
Serbia | Srpski(link is external)
Singapore | English(link is external)
Slovakia | Slovensky(link is external)
Slovenia | Slovenščina(link is external)
Slovenia | English(link is external)
South Africa | English(link is external)
Spain | Español(link is external)
Sweden | Svenska(link is external)
Switzerland | Deutsch(link is external)
Switzerland | Français(link is external)
Taiwan | 繁體中文(link is external)
Thailand | ภาษาไทย(link is external)
Türkiye | Türkçe(link is external)
United Kingdom | English(link is external)
United States | English(link is external)
    • About 

      • Board of Directors 

        • Giovanni Caforio 
        • Simon Moroney 
        • Nancy C. Andrews 
        • Ton Buechner 
        • Patrice Bula 
        • Elizabeth (Liz) Doherty 
        • Ana de Pro Gonzalo 
        • Bridgette Heller 
        • Daniel Hochstrasser 
        • Frans van Houten 
        • Elizabeth McNally 
        • John D. Young 
        • Charlotte Pamer-Wieser 
      • Executive Committee 

        • Vasant (Vas) Narasimhan 
        • Shreeram Aradhye 
        • Victor Bulto 
        • Aharon (Ronny) Gal 
        • Karen L. Hale 
        • Patrick Horber 
        • Harry Kirsch 
        • Rob Kowalski 
        • Steffen Lang 
        • Fiona Marshall 
        • Lutz Hegemann 
        • Teresa Jose 
        • Michelle Weese 
      • Products 
      • Therapeutic areas 

        • Cardiovascular, renal and metabolic 
        • Immunology 
        • Neuroscience 
        • Oncology 
      • People and culture 
      • Inclusion 

        • Promoting inclusion 
        • Building belonging 
        • Parental leave 
        • Caring for the mental health and wellbeing of our people 
      • Novartis Gene Therapies 
      • Manufacturing 
      • Quality 

        • Audit program 
        • Novartis quality management system (QMS) 
        • Product and patient safety training 
        • Regulatory inspections 
        • Product recalls 
        • Third-party suppliers 
      • Novartis and the European Union (EU) 
      • Awards and recognition 
      Mother and daughter cuddling on a bed in a kids room

      About

      Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach 296 million people worldwide.

    • Patients and caregivers 

      • Novartis commitment to patients and caregivers 
      • Diseases 
      • Patient organization funding 
      • Patients perspectives stories 
      Adult daughter talking to her senior parents on a bench in a park

      Patients and caregivers

      Information for patients and their caregivers including clinical trial recruiting, managed access programs, funding opportunities for patient organizations and side effects reporting.

    • Healthcare professionals 

      • Medical congresses and events 

        • ASCO Annual Meeting 
      • Products 
      • Novartis pipeline 
      • Managed access programs 

        • Zolgensma® Global Managed Access Program (gMAP) 
      • Novartis external funding 
      • Healthcare professional resources by country 
      • Investigator-initiated trials / studies 
      • Novartis medical information 

        • Submit medical enquiry 
      Doctor discussing illness with patient in an office

      Healthcare professionals

      Resources for physicians and other healthcare professionals including clinical trial recruiting, grant funding, congresses and country-level information.

    • Research and development 

      • Technology platforms 
      • Research disease areas 

        • Cardiovascular and metabolic disease research at Novartis 
        • DAx: exploratory disease research at Novartis 
        • Global Health disease area research at Novartis 
        • Immunology disease research at Novartis 
        • Neuroscience research at Novartis 
        • Oncology research at Novartis 
      • Novartis pipeline 
      • Research collaborations 
      • Collaborations 
      A female research scientist in a lab looking at a sample

      Research & development

      Discover how Novartis turns breakthrough science into transformative, high-value treatments.
       

    • ESG 

      • Access 

        • Creating sustainable business models 
        • Value-based pricing 
        • Sub-Saharan Africa 
        • Donations 
        • Novartis access principles 
        • Novartis oncology access 
        • Patents and licensing 
      • Environmental sustainability 

        • Climate 
        • Nature - Waste 
        • Nature - Water 
      • Ethics, risk and compliance 

        • Ethical behavior 
        • Compliance 
        • Human rights 
        • Learning and engagement 
        • Integrated risk assurance 
      • Global health 

        • Pandemic preparedness 
        • Avoidable blindness 
        • Chagas disease 
        • Leprosy 
        • Malaria 
        • Sickle cell disease (SCD) 
        • Novartis Foundation  (link is external)
      • Inclusion 
      • ESG index 
      • Reporting and transparency hub 

        • ESG rating performance 
        • Targets 
        • Patient organization funding 
        • Payments to healthcare professionals 
        • Public policy 
        • A living wage 
        • A safe workplace 
        • Animal research 
      Family and friends having a party at home

      Environmental, social and governance

      Learn about our commitments to making a positive impact on the world by providing access to innovative medicines, protecting the environment, and upholding high ethical standards. Explore the Novartis in Society Integrated Report.

    • Investors 

      • Event calendar 
      • Financial data 

        • Novartis annual results 
        • Novartis quarterly results 
        • Novartis SEC filings 
        • Product sales 
        • Fixed-income securities 
        • Expected currency impact 
      • Share data and analysis 

        • Share monitor 
        • Dividend information 
        • Share ownership 
        • Share overview 
        • Return on investment calculator 
      • Shareholder information 

        • General Meetings 
        • American Depositary Receipts (ADR) 
        • Share buyback 
        • Frequently asked questions 
      • Company overview 

        • Corporate governance 
      • Reporting and transparency hub 

        • Reporting archive 
        • ESG rating performance 
        • Publications order form 
      • ESG 
      Business woman working on her laptop in a bright atmosphere

      Investors

      Updates and resources for investors including financial information, disclosures, events, share price, ESG and reporting.

    • News 

      • Newsroom 
      • Media library  
      • Stories 
      • Subscribe 
      • Events 
      Overhead view of a meeting room with people in the foreground and screens in the background

      News

      Information for journalists including media releases, statements, stories, multimedia resources and more.

    • Careers 

      • Career search 
      • Our business functions 

        • Careers in research and development 
        • Careers in operations 
        • Careers in commercial and sales 
        • Careers in global functions 
      • Why Novartis 
      • Career hub 

        • Temporary contracts  (link is external)
      • Early careers 

        • Graduates 
        • Students 
        • US Biomedical Research internship programs 
        • Community exploration and learning lab (CELL) 
      Two business people

      Careers

      Novartis is hiring! Find open positions, learn more about our strategy and culture, and apply today.

    • Clinical trials 
    • Partnering 
    • Supplier portal 
    • Report side effects 
    • Contacts 
    Grandmother, mother and daughter smiling and laughing on a beach

    Home

    Working together, we can reimagine medicine to improve and extend people’s lives.

Global Search Navigation
  • All
    • Media library
    • Site pages
    • Press releases
    • Featured news
    • Stories
    • Clinical Trials
Hide Filters
Sort by
Sort by
Showing 2721 results
  • Press release / Jun 26, 2015

    Novartis drug Farydak® recommended by CHMP for EU approval to treat multiple myeloma, providing patients a new mechanism of action

    Farydak (panobinostat) combination improved PFS by 7.8 months for patients who received >=2 prior regimens including bortezomib and an IMiD[1] Farydak would be the first HDAC inhibitor with…
  • Press release / Jun 30, 2015

    Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches

    New features of the ViaOpta apps, previously available for iPhone and AndroidTM mobile phones, are also available to enhance the daily lives of people with visual impairments   These apps…
  • Press release / Jun 29, 2015

    Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.

    Acquisition adds novel angiotensin II Type 2 receptor antagonist for the treatment of neuropathic pain to Novartis' industry-leading development pipeline   Neuropathic pain is a chronic…
  • Press release / Jul 07, 2015

    Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization

    First in the world approval brings hope of longer life and fewer hospitalizations for millions of Americans with heart failure with reduced ejection fraction Entresto is the first and only treatment…
  • Press release / Jul 01, 2015

    Alcon receives European Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surgery

    AcrySof® IQ Aspheric Intraocular Lens (IOL) with UltraSertTM Pre-loaded Delivery System helps to maintain the integrity of the incision while facilitating smooth, consistent delivery of the IOL…
  • Press release / Jul 16, 2015

    Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients

    WHO prequalified Coartem® 80/480mg is the first and only  high strength malaria treatment available for donor-funded public sector procurement  Coartem® 80/480mg reduces the pill burden for…
  • Press release / Jul 21, 2015

    Novartis erzielt im zweiten Quartal eine solide Performance mit starken Innovationen und Fortschritten bei Neueinführungen

    Die fortzuführenden Geschäftsbereiche[2] steigern im zweiten Quartal den Umsatz, das operative Kernergebnis[1] und den Kerngewinn pro Aktie (kWk[1]): Der Nettoumsatz beläuft sich auf USD 12,7…
  • Press release / Jul 21, 2015

    Novartis: solide performance au deuxième trimestre grâce à la force de l'innovation et aux progrès des nouveaux lancements

    Croissance des ventes, du résultat opérationnel core[1] et du BPA core (tcc[1]) des activités poursuivies[2] au T2: Le chiffre d'affaires net s'est élevé à USD 12,7 milliards (-5%, +6% tcc). Le…
  • Press release / Jul 21, 2015

    Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches

    Sales, core[1] operating income and core EPS grew (cc[1]) for continuing operations[2] in Q2: Net sales amounted to USD 12.7 billion (-5%, +6% cc) Operating income was USD 2.3…
  • Press release / Jul 24, 2015

    Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blood disorder

    If approved, Revolade would be the first treatment option in its class in the EU for certain patients with SAA  Approximately 40% of SAA patients unresponsive to initial immunosuppressive…

Pagination

  • ‹ Previous page
  • 1
  • …
  • 262
  • 263
  • 264
  • 265
  • 266
  • 267
  • 268
  • …
  • 273
  • › Next page

Novartis

Working together
  • Patients and caregivers
  • Healthcare professionals
  • Researchers
  • Job seekers
  • Journalists
  • Investors
Topics
  • Access
  • ESG
  • SpeakUp
Explore
  • Pipeline
  • Products
  • Clinical trials
  • Partnering
  • Events
Therapeutic areas
  • Cardiovascular, renal and metabolic
  • Immunology
  • Neuroscience
  • Oncology
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
  • (link is external)
Footer Bottom
© 2025 Novartis AG
  • Terms of use
  • Privacy
  • Cookie settings
  • Contacts
  • Locations
  • Site map
  • Open source
  • Web accessibility
Novartis Site Directory
This site is intended for a global audience